These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 27614350)
61. Immunogenicity of fusion proteins. An example of tumor-specific/transformation-related antigens. Gambacorti-Passerini C Int J Clin Lab Res; 1993; 23(4):186-91. PubMed ID: 7510148 [TBL] [Abstract][Full Text] [Related]
62. Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer. Ouspenskaia T; Law T; Clauser KR; Klaeger S; Sarkizova S; Aguet F; Li B; Christian E; Knisbacher BA; Le PM; Hartigan CR; Keshishian H; Apffel A; Oliveira G; Zhang W; Chen S; Chow YT; Ji Z; Jungreis I; Shukla SA; Justesen S; Bachireddy P; Kellis M; Getz G; Hacohen N; Keskin DB; Carr SA; Wu CJ; Regev A Nat Biotechnol; 2022 Feb; 40(2):209-217. PubMed ID: 34663921 [TBL] [Abstract][Full Text] [Related]
63. Defined antigens recognized by T lymphocytes on human tumors. Coulie PG; Van Pel A Curr Opin Oncol; 1993 Nov; 5(6):1043-8. PubMed ID: 8305537 [TBL] [Abstract][Full Text] [Related]
64. Combined assessment of MHC binding and antigen abundance improves T cell epitope predictions. Koşaloğlu-Yalçın Z; Lee J; Greenbaum J; Schoenberger SP; Miller A; Kim YJ; Sette A; Nielsen M; Peters B iScience; 2022 Feb; 25(2):103850. PubMed ID: 35128348 [TBL] [Abstract][Full Text] [Related]
66. Cancer and depression: cancer presenting with depressive illness: an autoimmune disease? Brown JH; Paraskevas F Br J Psychiatry; 1982 Sep; 141():227-32. PubMed ID: 6182940 [TBL] [Abstract][Full Text] [Related]
67. Treatment of cancer by alteration of a cancer specific surface membrane epitope. Field EJ Med Hypotheses; 1986 Mar; 19(3):257-9. PubMed ID: 2421141 [TBL] [Abstract][Full Text] [Related]
74. Recent advances in T-cell engineering for use in immunotherapy. Sharma P; Kranz DM F1000Res; 2016; 5():. PubMed ID: 27703664 [TBL] [Abstract][Full Text] [Related]
75. Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich Tumor. Ngiow SF; Young A; Blake SJ; Hill GR; Yagita H; Teng MW; Korman AJ; Smyth MJ Cancer Res; 2016 Nov; 76(21):6266-6277. PubMed ID: 27634762 [TBL] [Abstract][Full Text] [Related]
76. Deep Mutational Scans as a Guide to Engineering High Affinity T Cell Receptor Interactions with Peptide-bound Major Histocompatibility Complex. Harris DT; Wang N; Riley TP; Anderson SD; Singh NK; Procko E; Baker BM; Kranz DM J Biol Chem; 2016 Nov; 291(47):24566-24578. PubMed ID: 27681597 [TBL] [Abstract][Full Text] [Related]
77. Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse. Kenderian SS; Porter DL; Gill S Biol Blood Marrow Transplant; 2017 Feb; 23(2):235-246. PubMed ID: 27638367 [TBL] [Abstract][Full Text] [Related]
78. Adoptive Transfer of Tumor-Specific Th2 Cells Eradicates Tumors by Triggering an In Situ Inflammatory Immune Response. Lorvik KB; Hammarström C; Fauskanger M; Haabeth OA; Zangani M; Haraldsen G; Bogen B; Corthay A Cancer Res; 2016 Dec; 76(23):6864-6876. PubMed ID: 27634753 [TBL] [Abstract][Full Text] [Related]
79. Expitope 2.0: a tool to assess immunotherapeutic antigens for their potential cross-reactivity against naturally expressed proteins in human tissues. Jaravine V; Mösch A; Raffegerst S; Schendel DJ; Frishman D BMC Cancer; 2017 Dec; 17(1):892. PubMed ID: 29282079 [TBL] [Abstract][Full Text] [Related]